INmune Bio, Inc. (NASDAQ:INMB) Position Lifted by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in INmune Bio, Inc. (NASDAQ:INMB) by 16.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 16,744 shares of the company’s stock after buying an additional 2,424 shares during the quarter. Rhumbline Advisers owned approximately 0.08% of INmune Bio worth $78,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Barclays PLC lifted its position in shares of INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after buying an additional 24,906 shares during the last quarter. Jane Street Group LLC bought a new position in shares of INmune Bio in the 3rd quarter worth about $79,000. Geode Capital Management LLC lifted its position in shares of INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock worth $1,857,000 after buying an additional 21,262 shares during the last quarter. State Street Corp lifted its position in shares of INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after buying an additional 58,838 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of INmune Bio in the 3rd quarter worth about $113,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Price Performance

INMB opened at $7.95 on Tuesday. INmune Bio, Inc. has a 12 month low of $4.32 and a 12 month high of $12.72. The stock has a market cap of $176.27 million, a P/E ratio of -3.65 and a beta of 1.93. The stock’s 50 day moving average price is $7.74 and its 200 day moving average price is $6.23.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on INMB shares. Scotiabank raised their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Maxim Group boosted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Rodman & Renshaw began coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, INmune Bio has a consensus rating of “Buy” and a consensus target price of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.